Clinical trial Recruiting at 1 site Interventional Ages 18 to 65

Three treatment options for myofascial back pain

Official title: COMPARATIVE EFFECTIVENESS OFF DRY NEEDLING, EXTRACORPOREAL SHOCK WAVE THERAPY, AND TRANSCUTANEOUS PULSED RADIOFREQUENCY IN PATIENTS WITH MYOFASCIAL PAIN SYNDROME: A PROSPECTIVE, RANDOMIZED CONTROLLED TRIAL

Run by Sakarya University · NCT07511751 · Data updated 2026-11-12

This trial will test whether dry needling, shock wave therapy (ESWT), or pulsed radiofrequency (PRF) reduces pain and improves function in adults 18–65 with chronic myofascial back pain.

Quick facts

Study typeInterventional
Ages18 Years to 65 Years
SexAll
Enrollment60 (estimated)
SponsorSakarya University
Academic / other
Locations1 site (Adapazarı, Sakarya)
StatusRecruiting
StartedMarch 10, 2026
Main results expectedMarch 10, 2027
Study endsMarch 10, 2027
Registry record updatedMay 7, 2026
Trial IDNCT07511751 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18–65 with clinically diagnosed myofascial pain syndrome causing back pain for at least three months who have not improved with conservative treatments are the ideal candidates.

Probably not a fit

Patients with fibromyalgia, recent cervical surgery or cervical disc pathology, shoulder pathologies, coagulation disorders or anticoagulant use, active infection, malignancy, or inflammatory spinal disease are unlikely to be eligible or to benefit from participation.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized, parallel-group trial will assign adults with clinically diagnosed myofascial back pain lasting at least three months to receive dry needling, extracorporeal shock wave therapy (ESWT), or pulsed radiofrequency (PRF). Treatments will be delivered at Sakarya Training and Research Hospital and outcomes measured before and after the interventions. Primary outcomes include pain intensity measured by the Numeric Rating Scale (NRS) and functional status, with follow-up assessments to compare short-term effects across groups. The study seeks to provide head-to-head comparative data to inform clinical choice among commonly used therapies.

Why it matters

Potential benefit: If successful, the study could identify which of the three treatments most effectively reduces pain and improves function for patients with myofascial back pain.

How similar studies have gone: Previous studies and reviews report some benefit for dry needling and ESWT in myofascial pain, while evidence for PRF is less consistent and direct comparative data are limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age between 18 and 65 years
* Clinically diagnosed myofascial pain syndrome
* Back pain lasting at least 3 months
* Failure to respond to conservative treatments

Exclusion Criteria:

* History of cervical surgery or cervical disc pathology
* Fibromyalgia
* Shoulder pathologies
* Coagulation disorders or use of anticoagulant therapy
* Infection, malignancy, or inflammatory spinal diseases

Where it's running

  • Sakarya Training and Research Hospital
    Adapazarı, Sakarya, Turkey (Türkiye)
    Recruiting

Study contacts

  • Principal investigator: KEMAL NAS, MD, Professor — Sakarya University Training and Research Hospital, Department of Algology
  • Study coordinator: AYSENUR IMAMOGLU BABA, MD,Resident
  • Email: aysenurimamoglub@gmail.com
  • Phone: +905437866097

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.